Skip to content
Boca Raton City Online – Lifestyle
Author:
Celcuity Inc.
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
June 1, 2026
Celcuity To Participate in Upcoming Investor Conferences
May 28, 2026
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
May 14, 2026
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
May 8, 2026
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
March 4, 2026
←
Previous Page
1
2